Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Net Cash Flow (2016 - 2025)

Spero Therapeutics' Net Cash Flow history spans 10 years, with the latest figure at -$8.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 64.31% year-over-year to -$8.4 million; the TTM value through Dec 2025 reached -$12.6 million, up 46.15%, while the annual FY2025 figure was -$12.6 million, 46.15% up from the prior year.
  • Net Cash Flow reached -$8.4 million in Q4 2025 per SPRO's latest filing, down from $17.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $58.7 million in Q4 2022 to a low of -$40.5 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$2.2 million, with a median of -$6.8 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: plummeted 659.75% in 2021, then skyrocketed 21431.27% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$275000.0 in 2021, then surged by 21431.27% to $58.7 million in 2022, then tumbled by 129.82% to -$17.5 million in 2023, then plummeted by 33.78% to -$23.4 million in 2024, then skyrocketed by 64.31% to -$8.4 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Net Cash Flow are -$8.4 million (Q4 2025), $17.4 million (Q3 2025), and -$17.7 million (Q2 2025).